tiprankstipranks
Trending News
More News >

NLS Pharmaceutics Extends Merger Agreement with Kadimastem

Story Highlights
NLS Pharmaceutics Extends Merger Agreement with Kadimastem

Don’t Miss TipRanks’ Half-Year Sale

An announcement from NLS Pharmaceutics ( (NLSP) ) is now available.

On July 1, 2025, NLS Pharmaceutics Ltd. announced a fifth amendment to its merger agreement with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd., extending the termination date to August 31, 2025. This extension allows the parties more time to complete the merger, demonstrating their commitment to fulfilling all regulatory requirements and aligning efforts for a successful merger completion.

More about NLS Pharmaceutics

NLS Pharmaceutics Ltd. is a company operating in the pharmaceutical industry, focusing on the development of therapeutics for the treatment of central nervous system disorders. The company is based in Zurich, Switzerland, and is involved in a merger with Kadimastem Ltd., an Israeli company.

Average Trading Volume: 274,986

Technical Sentiment Signal: Hold

Current Market Cap: $10.04M

Find detailed analytics on NLSP stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1